CD226 and ovarian cancer: Neutralizing antibodies targeting γδ TCRs, co-stimulation receptors NKG2D and DNAM-1, and death ligands FasL and TRAIL all efficiently impaired the killing of primary ovarian cancer cells by αPD-L1-γδ T cells (Fig. 4b).